NR4A1 and breast carcinoma: The EndoPredict assay is an RT-qPCR-based 12-gene test using RNA from FFPE tissue, specifically validated in two clinical studies for recurrence prediction in hormone receptor positive, HER2 negative, nodal negative and positive breast cancer treated with adjuvant hormonal therapy alone [18].